DOP2009000138A - Inhibidores de transcriptasa inversa no nucleósidicos - Google Patents

Inhibidores de transcriptasa inversa no nucleósidicos

Info

Publication number
DOP2009000138A
DOP2009000138A DO2009000138A DO2009000138A DOP2009000138A DO P2009000138 A DOP2009000138 A DO P2009000138A DO 2009000138 A DO2009000138 A DO 2009000138A DO 2009000138 A DO2009000138 A DO 2009000138A DO P2009000138 A DOP2009000138 A DO P2009000138A
Authority
DO
Dominican Republic
Prior art keywords
compounds
prophylaxis
reverse transcriptase
treatment
nucleosid
Prior art date
Application number
DO2009000138A
Other languages
English (en)
Inventor
Neville J Anthony
Robert Gomez
Samson M Jolly
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DOP2009000138A publication Critical patent/DOP2009000138A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Los compuestos de la fórmula I: son inhibidores de transcriptasa inversa de VIH, en la que Q, R2, R3, R6, T1, T2, y T3 se define en el presente documento. Los compuestos de la formula I, y sus sales y profarmacos farmaceuticamente aceptables, son de utilidad en la inhibicion de transcriptasa inversa de VIH, en la profilaxis y tratamiento de infeccion por VIH y en la profilaxis, retraso del inicio o de la progresion, y tratamiento del SIDA. Los compuestos y sus sales pueden emplearse como ingredientes en composiciones farmaceuticas, opcionalmente combinados con otros antivirales, inmunomoduladores, antibioticos o vacunas. son inhibidores de trasnscriptasa inversa de VIH, en la que Q, R2, R3, R6, T1, T2, T3 se define en el presente documento. Los compuestos de la Fórmula I, y sus sales y profármacos farmacéuticamente aceptables, son de utilidad en la inhibición de transcriptasa inversa de VIH, en la profilasis y tratamiento de infección por VIH y en la profilasis, retraso del inicio o de la progresión, y tratamiento del SIDA. Los compuestos y sus sales pueden emplearse como ingredientes en composiciones farmacéuticas, opcionalmente combinados con otros antivirales, inmonomoduladores, antibióticos o vacunas.
DO2009000138A 2006-12-13 2009-06-12 Inhibidores de transcriptasa inversa no nucleósidicos DOP2009000138A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87462906P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
DOP2009000138A true DOP2009000138A (es) 2009-11-15

Family

ID=39277099

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000138A DOP2009000138A (es) 2006-12-13 2009-06-12 Inhibidores de transcriptasa inversa no nucleósidicos

Country Status (29)

Country Link
US (2) US7781454B2 (es)
EP (1) EP2121638B1 (es)
JP (1) JP5123949B2 (es)
KR (1) KR20090087481A (es)
CN (1) CN101558050A (es)
AR (1) AR064199A1 (es)
AU (1) AU2007334598B2 (es)
BR (1) BRPI0720196A2 (es)
CA (1) CA2673093A1 (es)
CL (1) CL2007003594A1 (es)
CR (1) CR10843A (es)
DO (1) DOP2009000138A (es)
EA (1) EA200970572A1 (es)
EC (1) ECSP099373A (es)
GE (1) GEP20115320B (es)
GT (1) GT200900158A (es)
HN (1) HN2009001160A (es)
IL (1) IL199103A0 (es)
MA (1) MA31036B1 (es)
MX (1) MX2009006285A (es)
NI (1) NI200900103A (es)
NO (1) NO20092636L (es)
NZ (1) NZ577637A (es)
PE (1) PE20081448A1 (es)
SV (1) SV2009003294A (es)
TN (1) TN2009000243A1 (es)
TW (1) TW200831085A (es)
WO (2) WO2008076225A2 (es)
ZA (1) ZA200903395B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR20100080597A (ko) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2705338A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
KR20100088142A (ko) * 2007-11-20 2010-08-06 머크 샤프 앤드 돔 코포레이션 비-뉴클레오사이드 역전사효소 억제제
WO2009117278A2 (en) * 2008-03-20 2009-09-24 Merck & Co., Inc. Processes for preparing (amino-pyrazolopyridinyl)methoxy substituted biaryl ethers
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
PL2924034T3 (pl) 2010-03-30 2017-07-31 Merck Canada Inc. Kompozycja farmaceutyczna zawierająca nienukleozydowy inhibitor odwrotnej transkryptazy
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US20120142627A1 (en) * 2010-12-06 2012-06-07 Emory University Monophosphate prodrugs of dapd and analogs thereof
WO2013025449A1 (en) * 2011-08-16 2013-02-21 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN103848827A (zh) * 2012-11-30 2014-06-11 南京大学 一种含苯并三氮唑类衍生物在抗癌药物中的应用
CN103848826A (zh) * 2012-11-30 2014-06-11 南京大学 一类含苯并三氮唑结构的1,3,4-恶二唑类衍生物的制法与用途
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
NO3074400T3 (es) 2013-11-26 2018-04-14
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
EP3122751B1 (en) 2014-03-26 2019-10-30 F.Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EP3785714A1 (en) 2014-04-01 2021-03-03 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
CN107635995B (zh) 2015-09-24 2022-08-19 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
KR20180054634A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물
MX2017015034A (es) 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
CN105906482B (zh) * 2016-05-19 2019-02-12 江苏优嘉植物保护有限公司 一种利用2,5-二氯酚醚制备2,5-二氯苯酚的方法
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
EP3898595B1 (en) 2018-12-18 2024-05-01 Merck Sharp & Dohme LLC Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
AU2020295721B2 (en) 2019-06-21 2025-04-03 Ascendis Pharma A/S Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds
US20230024438A1 (en) * 2019-12-04 2023-01-26 Arcus Biosciences, Inc. Inhibitors of hif-2alpha
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
IL319671A (en) 2022-09-26 2025-05-01 Edgewise Therapeutics Inc 4,1-Dihydroquinazolinone compounds and their uses
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用
EP4688748A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
WO2026042788A1 (ja) * 2024-08-20 2026-02-26 塩野義製薬株式会社 複素環誘導体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
SU1049487A1 (ru) * 1982-06-24 1983-10-23 Новокузнецкий научно-исследовательский химико-фармацевтический институт Способ получени @ -аминокетонов бензимидазольного р да
US5358950A (en) * 1991-07-05 1994-10-25 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
ATE238998T1 (de) * 1997-02-25 2003-05-15 Us Gov Health & Human Serv Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
US6977262B2 (en) 2001-02-02 2005-12-20 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
JP2006500355A (ja) 2002-08-07 2006-01-05 イデニクス（ケイマン）リミテツド Ｈｉｖ治療用の置換フェニルインドール類
CA2500083A1 (en) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
MXPA05009459A (es) 2003-03-03 2006-05-17 Array Biopharma Inc Inhibidores de p38 y sus metodos de uso.
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
JP2007523938A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾールの縮合誘導体
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
WO2005115147A2 (en) * 2004-05-18 2005-12-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
CA2574308C (en) 2004-07-27 2014-03-25 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
WO2006102112A2 (en) * 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Prokineticin 1 receptor
WO2007002481A2 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
CA2612554A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
JP2008546839A (ja) 2005-06-28 2008-12-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド逆転写酵素阻害剤
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
WO2008058867A2 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
NZ577637A (en) 2011-05-27
WO2008076225A2 (en) 2008-06-26
TW200831085A (en) 2008-08-01
IL199103A0 (en) 2010-03-28
JP2010510989A (ja) 2010-04-08
PE20081448A1 (es) 2008-10-19
ZA200903395B (en) 2010-05-26
AU2007334598B2 (en) 2013-01-17
JP5123949B2 (ja) 2013-01-23
US20080275097A1 (en) 2008-11-06
CA2673093A1 (en) 2008-06-26
TN2009000243A1 (en) 2010-10-18
US20100286192A1 (en) 2010-11-11
MX2009006285A (es) 2009-06-23
GEP20115320B (en) 2011-10-25
EP2121638B1 (en) 2016-05-25
GT200900158A (es) 2009-10-14
NO20092636L (no) 2009-09-08
ECSP099373A (es) 2009-07-31
HN2009001160A (es) 2011-10-11
CR10843A (es) 2009-08-12
SV2009003294A (es) 2009-11-09
AU2007334598A1 (en) 2008-06-26
WO2008076223A1 (en) 2008-06-26
NI200900103A (es) 2010-01-26
BRPI0720196A2 (pt) 2013-12-31
KR20090087481A (ko) 2009-08-17
AR064199A1 (es) 2009-03-18
MA31036B1 (fr) 2009-12-01
CL2007003594A1 (es) 2008-05-30
US7781454B2 (en) 2010-08-24
WO2008076225A3 (en) 2008-08-07
CN101558050A (zh) 2009-10-14
EA200970572A1 (ru) 2009-12-30
EP2121638A2 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
ECSP099373A (es) Inhibidores de transcriptasa inversa no nucleosídicos
ECSP12012201A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
NI201500048A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
MX388757B (es) Profármacos de éster alifático antivíricos de tenofovir.
ECSP066826A (es) Inhibidores de integrasa de vih
CO6382127A2 (es) Inhibidores de la integrasa del vih
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
DOP2006000176A (es) Inhibidores de la transcriptasa reversa de vih
ECSP088126A (es) Inhibidores de la transcriptasa reversa de vih
DOP2005000105A (es) Inhibidores de la integrasa del vih